Zobrazeno 1 - 10
of 19
pro vyhledávání: '"Shivani K, Mhatre"'
Autor:
Chen Li, Ana Ferro, Shivani K. Mhatre, Danny Lu, Marcus Lawrance, Xiao Li, Shi Li, Simon Allen, Jayesh Desai, Marwan Fakih, Michael Cecchini, Katrina S. Pedersen, Tae You Kim, Irmarie Reyes-Rivera, Neil H. Segal, Christelle Lenain
Publikováno v:
Communications Medicine, Vol 2, Iss 1, Pp 1-8 (2022)
Li et al. report outcomes from the atezolizumab/isatuximab arm of the phase Ib/II MORPHEUS-CRC trial in patients with metastatic colorectal cancer. In addition, the authors leverage historical control data from the phase III IMblaze370 study to provi
Externí odkaz:
https://doaj.org/article/a2d8a6d7f97440f4b6e89b19aac1153c
Autor:
Sumanta Pal, Jun Gong, Shivani K. Mhatre, Shih-Wen Lin, Andy Surinach, Sarika Ogale, Rini Vohra, Herschel Wallen, Daniel George
Publikováno v:
BMC Cancer, Vol 19, Iss 1, Pp 1-15 (2019)
Abstract Background Vascular endothelial growth factor (VEGF), tyrosine kinase (TK) and mechanistic target of rapamycin kinase (mTOR) inhibitors are common first-line (1 L) treatments for metastatic renal cell carcinoma (mRCC). Despite treatment avai
Externí odkaz:
https://doaj.org/article/bd75bbb11ff940f29a493320bc5a235e
Autor:
Andy Surinach, Sumanta K. Pal, Shivani K. Mhatre, Rini Vohra, Sarika Ogale, Daniel J. George, Herschel Wallen, Shih-Wen Lin, Jun Gong
Publikováno v:
BMC Cancer, Vol 19, Iss 1, Pp 1-15 (2019)
BMC Cancer
BMC Cancer
Background Vascular endothelial growth factor (VEGF), tyrosine kinase (TK) and mechanistic target of rapamycin kinase (mTOR) inhibitors are common first-line (1 L) treatments for metastatic renal cell carcinoma (mRCC). Despite treatment availability,
Autor:
Viraj Degaonkar, Petros Grivas, Karim Chamie, Nicole N. Davarpanah, Alexandra Drakaki, Allan J. Pantuck, Preet K. Dhillon, Shivani K. Mhatre, Andy Surinach
Publikováno v:
Urologic oncology. 39(1)
Introduction There is no current standard of care for patients with high-risk muscle-invasive urothelial carcinoma (MIUC) after neoadjuvant chemotherapy and surgical resection or for those who cannot receive or decline cisplatin-based perioperative c
Publikováno v:
Journal of American College Health. 66:237-245
OBJECTIVE To compare three over-the-counter (OTC) Drug Facts panel versions for information processing optimization among college students. PARTICIPANTS University of Houston students (N = 210) participated in a cross-sectional survey from January to
Publikováno v:
Journal of Pharmaceutical Health Services Research. 8:123-130
Objectives The purpose of this study was to evaluate the association between patients’ perceived relationship with their pharmacist and physicians and its association with their beliefs in medicine. Methods A cross-sectional design was used and 307
Autor:
Susheela Carroll, Julie N. Graff, Sumati Gupta, Robert Dreicer, Brian C. Sauer, Catherine Li, Vikas Patil, Ahmad Halwani, Sujata Narayanan, Christina Yong, Kelli M Rasmussen, Zachary Burningham, Shivani K. Mhatre, Shih-Wen Lin
Publikováno v:
Urologic Oncology: Seminars and Original Investigations. 38:1.e1-1.e10
Background Metastatic castration-resistant prostate cancer (mCRPC) is incurable, with most patients surviving less than 3 years. However, many treatments that extend survival have been approved in the past decade. Objective To describe the patient de
Autor:
Shivani K. Mhatre, Sujit S. Sansgiry
Publikováno v:
Hepatology Research. 46:29-39
Aim The Food and Drug Administration guidelines emphasize that patient-reported outcome (PRO) instruments used in clinical trials must be developed based on a conceptual model, yet existing PRO instruments currently used in clinical trials of hepatit
Autor:
Sujit S. Sansgiry, Shivani K. Mhatre
Publikováno v:
Geriatrics & Gerontology International. 16:103-110
Aim The objectives of the present study were to test Spilker's quality of life model in the elderly population consuming over-the-counter (OTC) medications. It was hypothesized that OTC medication misuse increases adverse drug events (ADEs), ADEs as
Autor:
Shivani K. Mhatre, Sujit S. Sansgiry
Publikováno v:
Value in Health. 18(3)